IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

Study data demonstrated the high efficacy and safety of IceCure's ProSense cryoablation system, with a 100% complete ablation rate and no observed complications. Patients underwent observations at three, six, nine, and 12 months and biannually after the first year. The study reported a 100% initial complete ablation rate with no complications in any of the 56 ablations. However, four cases experienced local tumor progression, resulting in a progression rate of 8.9% This month,IceCure received marketing auth ...